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Aim: This review article presents a comprehensive overview of the literature on sex
hormones (estrogens, androgens, progesterone) and optic nerve disorders, with a
discussion of the implications for therapy and prevention.
Methods: Epidemiological, pre-clinical and clinical studies were reviewed.
Results: Analysis of the biological basis for a relationship between eye diseases and
sex hormones showed that some types of hormones can exert a protective effect either
directly on the retina and optic nerve or indirectly by modulating ocular blood flow. For
example, it seems that estrogen exposure has a protective effect against glaucoma,
whereas its deficit may lead to early onset of the disease. If further studies confirm the
data in the literature, estrogen therapy, because of its antioxidant action, may be effective
in the treatment of Leber’s hereditary optic neuropathy, whereas, in the light of current
studies, there does not seem to be an influence of estrogen on non-arteritic anterior
ischemic optic neuritis (NAION).
Conclusions: Although there is some evidence that in some optic nerve pathologies
the sex hormones seem to play an important role there are still too few studies providing
evidence for its wider use in clinical practice.
Keywords: gonadal hormones, estrogens, hormone therapy, eye disorders, glaucoma, optic nerve diseases,
sex-related differences
INTRODUCTION
There is growing evidence for interaction between gonadal hormones and diseases involving body
systems other than the reproductive organs (Rosner et al., 2013; Eisner, 2015). Some correlations,
like those between estrogens and bone metabolism, are well established (Clarke and Khosla, 2010;
Eisner, 2015), whereas others, particularly as regards the eye, are less evident. Estrogens, however,
seem to exert a neuroprotective effect (Azcoitia et al., 2011; Melcangi et al., 2011), a vascular effect
(Toker et al., 2003a; Faria et al., 2011; Schmidl et al., 2015), an intraocular pressure (IOP) regulation
effect (Weinreb and Khaw, 2004; Tehrani, 2015) and a support action against lamina cribrosa.
These evidences support the hypothesis that sex hormones may be involved in the pathogenesis
of eye diseases, such neuropathies as glaucoma, but also retinic diseases, as age-related macular
degeneration (AMD), and diseases of the lens, as cataracts. It may also be speculated that hormone
replacement therapy (HRT) in postmenopausal women can influence the course of these disorders
and be useful in the treatment of eye diseases (Hutchinson et al., 2014; Nuzzi et al., 2018; Table 1).
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This review article presents an overview of the literature on
sex hormones and optic nerve disorders, with a discussion of the
implications for therapy and prevention.
BIOLOGICAL AND EPIDEMIOLOGICAL
BASIS FOR THE INTERACTION BETWEEN
SEX HORMONES AND THE EYE
As recently reviewed by us in a review aimed at outlining
the current knowledge on the possible activity carried out
by sex hormones on retinal physiopathology (Nuzzi et al.,
2018), the long-held notion that the eye was “sex-neutral” has
no significance today, and a number of studies have, on the
contrary, provided several data in favor of a close interaction
between gonadal hormones and eye function. In brief, androgen,
estrogen, and progesterone receptors (or the expression of
their mRNA) have been demonstrated in many different ocular
tissues, including the lachrymal and meibomian glands, the
bulbar palpebral conjunctiva, the corneal surface, the ciliary
body of the lens, and the chorioretinal complex (Rocha et al.,
2000; Wickham et al., 2000; Gupta et al., 2005). In addition,
the retina produces neuroactive steroids by local synthesis
of cholesterol via the neurosteroidogenic pathway (Cascio
et al., 2015; Nuzzi et al., 2018). Changes in the availability of
neuroactive steroid following local insults have been implicated
in the adaptation of retinal cells to insults (Guarnieri et al., 2003).
Age and sex may influence the distribution of gonadal
hormone receptors throughout ocular tissues, and this has
been related with the differences in the epidemiology of certain
disorders (Gupta et al., 2005). For example estrogen receptor
alpha (ER-α) is present in the retina and retinal pigment
epithelium of young women but not in that of postmenopausal
women or men (Ogueta et al., 1999), while Munaut et al. (2001)
found ER-β in the human retina of male and female subjects.
Studies, using multifocal electroretinography, investigated the
differences in humans, taking into account not only the gender,
but also the age of the subjects; this allowed to demonstrate
that the differences in retinal function of men and women
were significant before the age of 50, while at a later age the
results were overlapping. Comparing the results of all these
groups with those of women who had undergone hysterectomy
and ovariectomy during reproductive age and so experienced
iatrogenic menopause, it emerged that the latter had the
worst retinal function, underlining the benefits of exposure to
estrogenic cycles (Ozawa et al., 2014).
Such anatomical and physiological differences are also
reflected in disease processes. For example, estrogens exert a
protective effect against cataracts during women’s reproductive
Abbreviations: ADSC, adipose-derived mesenchymal stem cell; AMD, age-
related macular degeneration; ER-α, estrogen receptor alpha; HRT, hormone
replacement therapy; IOP, intraocular pressure; LHON, Leber’s hereditary optic
neuropathy; MS, multiple sclerosis; NAION, nonarteritic anterior ischemic
optic neuropathy; OC, oral contraceptive therapy; OCT, optical coherence
tomography; PCOS, polycystic ovary syndrome; POAG, primary open-angle
glaucoma; RGC, retinal ganglion cell; RNFL, nerve fiber layer; SNPs, single
nucleotide polymorphisms.
years until the onset of menopause, when the risk of developing
cataracts increases over that for men (Zetterberg and Celojevic,
2015). Although an age/sex correlation for the incidence of
certain diseases has not been well established, some studies
have found that women are more often affected by closed angle
glaucoma and certain forms of AMD (e.g., neovascular AMD),
whereas primary open-angle glaucoma (POAG) and diabetic
retinopathy are more prevalent among men (Zetterberg, 2016).
Sex hormones’ influence seems to be present not only in
pathologies that primarily affect the optic nerve, but also in those
in which the involvement of the nerve is secondary, as diabetic
retinopathy.
Akar et al. (2005a) examined the effect of the menstrual
cycle on the optic nerve head in women with type 2 diabetes
and found significant changes (in particular an increase in the
neuroretinal rim area and a significant reduction in cup-shape
measure) that occur in the luteal phase in women with severe
diabetic retinopathy, but that not occur in women with mild
diabetic retinopathy and in healthy subjects. The study suggested
that normal hormonal fluctuations during the menstrual cycle
may affect the optic nerve only in cases of advanced disease.
It has been established that hormones, in particular estrogens
and progesterone, cause physiological changes on most ocular
structures; these changes can determine, in predisposed subjects,
the appearance of new conditions or the evolution of pre-
existing pathologies. Naderan (2018) investigated the role
that hormonal changes related to pregnancy have on ocular
physiopathology; they observed that some new conditions that
often occur during pregnancy are ocular dryness, associated
with or without contact lens intolerance, chloasma (Bolanca
et al., 2008) (a skin pigmentation localized specially in the face
and that mostly appears during pregnancy) and ocular ptosis
(Sanke, 1984) (the lowering of the eyelids), phenomena which
resolve spontaneously in most cases after childbirth. In some
ocular structures, during pregnancy, physiological changes occur
due to the increased water retention favored by the increase
of estrogenic levels. This happens for example in the cornea,
causing an increase in the thickness of the central portion,
which is expressed with refractive changes (Sharma et al., 2006;
Gotovac et al., 2013; Mehdizadehkashi et al., 2014), and at the
lens level (Beneyto and Pérez, 2006), with possible appearance
of cataract or worsening of a pre-existing condition. Among the
pathological ocular conditions most frequently associated with
pregnancy there are diabetic retinopathy (Klein et al., 1990),
which often progresses rapidly during this period, and central
serous chorioretinitis (Liu et al., 2016), of which pregnancy is
a risk factor, which resolves spontaneously, usually within 3
months of giving birth. According to some studies (Yust-Katz
et al., 2014) also gliomas would show a greater risk of progression
during pregnancy, especially if Grade II and III. van Westrhenen
et al. (2018) shown that pregnancy can be related both to a clinical
deterioration and to an increase in tumor size when imaged
with an magnetic resonance imaging scanner. Instead, other
pre-existing diseases improve during pregnancy, a phenomenon
that supports the neuroprotective effect of sex hormones. Among
them are uveitis (Chiam and Lim, 2014), in which both hormonal
and immunological changes related to pregnancy play a role, and
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TABLE 1 | Basis of interaction between sex hormones and the eye.
Biological basis Presence of androgen, estrogen, and progesterone receptors (or the expression of their mRNA) in many different ocular tissues
(Rocha et al., 2000; Wickham et al., 2000; Gupta et al., 2005)
Retina produces neuroactive steroids by local synthesis of cholesterol via the neurosteroidogenic pathway (Cascio et al., 2015)
Differences in retinal function of human men and women are significant before the age of 50, while at a later age the results are
overlapping (Ozawa et al., 2014).
Women who had undergone hysterectomy during reproductive age have a retinal function worse than other women and men (Ozawa
et al., 2014).
Normal hormonal fluctuations during the menstrual cycle affect the optic nerve in women with severe type 2 diabetes (Naderan, 2018)
Changes in hormone levels during pregnancy determine physiological changes on most ocular structures (Sanke, 1984; Bolanca
et al., 2008)
Epidemiological
basis
In women, estrogens exert a protective effect against cataracts until the onset of menopause, when the risk of developing cataracts
increases over that for men (Zetterberg and Celojevic, 2015).
Women are more often affected by closed angle glaucoma and certain forms of AMD (e.g., neovascular AMD), whereas primary
open-angle glaucoma and diabetic retinopathy are more prevalent among men (Zetterberg, 2016)
Neuroprotective
effect
17β-estradiol and nonfeminizing estrogen analogs protect retinal photoreceptor neurons from glutamate-induced damage (Gotovac
et al., 2013).
Neuroprotective action was found not only for estrogens but also for molecules with similar phenolic components (Sharma et al.,
2006).
Substitutive phytoestrogen therapy has neuroprotective effects similar to those observed using estrogens (Beneyto and Pérez, 2006).
There is an inferior decrease in retinal ganglion cell density in non-ovariectomized mice and a protective effect against
axotomy-induced RGC damage in the ovariectomized mice administered intravitreal exogenous estrogens (Klein et al., 1990).
Estrogens, via their anti-inflammatory action, inhibit or downregulate cytokine production (Yust-Katz et al., 2014)
Effect on ocular
hemodynamics
In central retinal artery and in ophthalmic artery vascular resistance is lower and blood flow velocity is higher in premenopausal
women than postmenopausal women and men (Toker et al., 2003a; Faria et al., 2011; Schmidl et al., 2015).
Infero-temporal retinal artery flow was greater in postmenopausal women receiving HRT than in those not receiving it (Akar et al.,
2005b)
AMD, age-related macular degeneration; RGC, retinal ganglion cell; HRT, hormone replacement therapy.
especially glaucoma, which is positively affected by the action of
progesterone, which seems to play a fundamental role, even if
not yet fully clarified, in lowering the IOP (Akar et al., 2005b).
To further understand if sex hormones play a role in the
pathophysiology of the retina and optic nerve, some studies
focused on the analysis of the thickness of the macular region
and the retinal nerve fiber layers (RNFL) in patients with
polycystic ovary syndrome (PCOS), an endocrine-gynecological
pathology characterized by the presence of ovarian microcysts,
menstrual irregularities and hyperandrogenism, often associated
with alterations of glucose metabolism, in particular with insulin
resistance, glucose intolerance and type 2 diabetes. Demir et al.
(2013) highlighted, by measuring the RNFL and ganglion cell
complex thicknesses by optical coherence tomography (OCT),
that the average thickness of the RNLF in the different sectors
was significantly higher in women with PCOS than in healthy
women. A few years later, the results obtained by this study
were extended by another group of researchers (de Souza-Júnior
et al., 2015), which showed that PCOS seems to play, thanks
to the trophic action of testosterone, a protective role on the
RNFL around the optic nerve, increasing its thickness, but
only if there are no other metabolic abnormalities, because if
these are present, PCOS would seem to perform a negative
action, reducing RNFL and total macular thickness. The effect of
PCOS at the ocular level also manifests itself in the alterations
induced on the ocular hemodynamics: in patients with PCOS
ocular blood flow velocity is increased and at the level of the
ophthalmic artery the vascular resistance seems to decrease
(Örnek et al., 2015).
In light of this evidence, it is clear that sex hormones are
involved in the physiological homeostasis of ocular tissues,
as evidenced by the presence of specific receptors in various
structures that compose the eye, and that in some pathologies
these hormones play a role of modulation, protective or
pathogenic, according to the specific condition analyzed.
NEUROPROTECTIVE EFFECT OF
GONADAL HORMONES
One of the aims of studies on the interaction between sex
hormones and the eye is to evaluate the neuroprotective
action these hormones, estrogens in particular, appear to have.
Estrogens protect retinal photoreceptor neurons from glutamate-
induced damage (Nixon and Simpkins, 2012) and this action is
probably mediated by membrane estrogen receptor (GPR30),
which is also expressed in the retina (Mangiamele et al., 2017).
Estrogens, but also similar non estrogenic phenolic
components, may also exert antioxidant neuroprotective
effects (Moosmann and Behl, 1999). This observation suggests
the possibility of treatments based with nonfeminizing estrogen
analogs and phenolic molecules that, despite having similar
neuroprotective effects to estrogen, should show fewer side
effects. For example, by studying the ocular function of
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postmenopausal women using short wavelength perimetry, it
has been observed that a substitutive phytoestrogen therapy has
effects similar to those observed using estrogens (Eisner and
Demirel, 2011).
To determine whether endogenous and exogenous estrogens
differed in action, Nakazawa et al. (2006) used a rodent model
of axotomy-induced retinal ganglion cell (RGC) degeneration
in glaucoma in ovariectomized and non-ovariectomized mice.
They observed a significantly reduced decrease in retinal
ganglion cell density in the non-ovariectomized mice, suggesting
an effect of endogenous estrogens. In addition, they noted a
protective effect against axotomy-induced RGC damage in
the ovariectomized mice administered intravitreal exogenous
estrogens. These results seem to indicate that exogenous
hormones have a protective action similar to that of endogenous
hormones.
Another possible source of damage to the optic nerve is
thought to be the activation of inflammatory pathways by
proinflammatory mediators, and by cytokines in particular
(Clzonkowska et al., 2006). It has been demonstrated that
estrogens, via their anti-inflammatory action, inhibit or
downregulate cytokine production (Baker et al., 2004). This
beneficial effect may partly explain sex-related differences in
certain diseases, and in those with an inflammatory component
TABLE 2 | Role of sex hormones in optic nerve disorders. For and against
evidences, with type of correlation.
Protective
effect
(+)
No difference or
non-protective effect
(–)
Unclear effect
(±)
Disease Estrogen Studies
Glaucoma + Dewundara et al., 2016
+ Vajaranant and Pasquae,
2012
+ Akar et al., 2004
+ Shin et al., 2018
+ Chen et al., 2018
LHON + Giordano et al., 2011
+ Pisano et al., 2015
NAION – Bernstein et al., 2007
Optic Neuritis ± Costello et al., 2012
Glioma and
meningioma
± Anic et al., 2014
± Felini et al., 2009
± Benson et al., 2015
+ Krishnamachari et al., 2014
+ Qi et al., 2013.
– Andersen et al., 2013a
– Michaud et al., 2010
– Claus et al., 2013
LHON, Leber’s hereditary optic neuropathy; NAOIN, non-arteritic anterior ischemic optic
neuropathy.
in particular. The initial phase of many neurodegenerative
diseases is characterized by damage caused by a primary event
to which the body mounts an inflammatory response. Though
activated as a protective response to injury, it also results in
further tissue damage. Estrogens could provide protection
against such diseases by mitigating the initial inflammatory
response associated with them.
Building on the observation that estrogens exert a
neuroprotective effect on the retina and optic nerve, researchers
applied this knowledge to determine whether other sex hormones
such as progesterone had a similar effect. Experimental studies on
animal models found no significant differences (Kaldi and Berta,
2004), however, more recent studies have reopened the question,
demonstrating that norgestrel, an analog of progesterone, would
play a neuroprotective role in retinal degeneration in retinitis
pigmentosa (Ruiz Lopez et al., 2017).
EFFECT OF GONADAL HORMONES ON
OCULAR HEMODYNAMICS
An essential action of gonadal hormones is to regulate ocular
blood flow (Toker et al., 2003a; Schmidl et al., 2015), which
indirectly affects neurotrophism and eye function. Numerous
studies have investigated how and to what extent these hormones
are involved in blood flow regulation and are implicated in
pathogenic processes triggered by hemodynamic abnormalities.
The beneficial effect of estrogens has been correlated with their
vasodilatory properties, which, by determining lower vascular
resistances, guarantee a greater blood flow, especially in larger
vessels (Dechênes et al., 2010; Schmidl et al., 2015). In fact, in
central retinal artery and in ophthalmic artery vascular resistance
is lower and blood flow velocity is higher in premenopausal
women in which endogenous estrogen levels are naturally higher,
or in women who received exogenous estrogens (Schmidl et al.,
2015), than in postmenopausal women exposed or not to HRT
(Toker et al., 2003a; Faria et al., 2011). In contrast, androgens
(Dechênes et al., 2010) and progesterone (Viana et al., 2011;
Souza et al., 2013) reduce retinal blood flow by antagonizing
estrogen activity.
SEX-RELATED DIFFERENCES IN
RELATION TO OPTIC NERVE DISEASE
There is growing evidence for links between sex hormones and
some important optic nerve diseases, including glaucoma, Leber’s
hereditary optic neuropathy, nonarteritic anterior ischemic optic
neuropathy, optic neuritis and optic nerve tumors, especially
gliomas. In this section of the review we proceed to collect
and summarize the main information currently present in the
literature about the association between the aforementioned
pathologies and sexual hormones.
Glaucoma
Glaucoma is a neurodegenerative disease that affects the
optic nerve, characterized by the gradual damage of retinal
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ganglion cells and their axons, that compose the optic nerve
(Schmidt et al., 2008).
Since these cells play a critical role in the process of vision, the
disease manifests itself with a decrease in visual acuity, of variable
entity depending on the type of glaucoma and the modalities of
onset (Yücel et al., 2003). It represents the second most common
cause of blindness in the world (Tham et al., 2014) and it is
therefore important to study in depth all the factors that influence
this pathology, including estrogens.
The analysis of various studies (Dewundara et al., 2016)
showed that the factors modulating the duration of exposure
to estrogens seem to influence the risk of developing a POAG:
prolonged exposure to estrogens, such as that occurring in
women entering menopause after age 54 (Pasquale and Kang,
2011), leads to a lower risk of developing POAG. On the
contrary, all the conditions reducing the duration of exposure
to estrogen such as the age at menarche over 13 years (Lee et al.,
2003), bilateral ovariectomy before age of 43 (Vajaranant et al.,
2014), or spontaneous menopause before age of 45 (Hulsman
et al., 2001), but also oral contraceptive therapy (OC) for more
than 5 years (Pasquale and Kang, 2011), increase the risk of
developing POAG. Finally, during pregnancy, especially during
the third trimester, in which estrogen levels are very high, a
reduction in IOP is observed (Qureshi, 1995; Qureshi et al.,
1996; Naderan, 2018). The role of HRT for menopause is still
uncertain (Sator et al., 1997; Toker et al., 2003b; Altinta et al.,
2004), although some studies have shown a beneficial effect
in terms of reducing the risk of developing POAG (Tehrani,
2015). Another recent study (Shin et al., 2018), conducted
on the Korean population, identified a statistically significant
association between the risk of developing POAG and female
reproductive factors only in the case of early menopause (before
age 45); in this study, other factors such as the age of menarche,
pregnancy, breastfeeding, use of contraceptive or replacement
therapies were not significant in modifying the incidence of
POAG.
Several more recent studies confirmed and expanded the
hypothesis of the influence of estrogen on glaucoma: it has
been highlighted, for example, that estrogens appear involved
in the process of formation and drainage of the aqueous humor,
key elements in the pathogenesis of glaucoma (Ogueta et al.,
1999; Altinta et al., 2004). IOP, which is fundamental for
optic nerve tropism, also seems to be influenced by changes
in estrogen concentration (Weinreb and Khaw, 2004). Many
studies have focused on the estrogen-IOP relationship: (Tehrani,
2015) has produced a review in which, after having verified
the existence of epidemiological differences concerning the
incidence of glaucoma in the two genders, analyzed not
only the action of endogenous estrogens, but also the role of
exogenous estrogens, administered as OC therapy or as HRT in
menopausal women. From this evaluation it emerges that the
IOP and the risk of developing glaucoma vary depending on the
hormone concentration: in particular, HRT in postmenopause
women would seem to reduce the risk of glaucoma, while
in premenopausal women an OC therapy would lead to an
increased risk. Tehrani hypothesizes that the opposite effect that
the two types of therapy exert on the risk of developing glaucoma
may depend both on the different hormone formulation of the
two therapies, and on the fact that the OC therapy suppress
ovulation, going to alter the physiological hormone levels of
the menstrual cycle, which causes a reduction in the total
endogenous estrogens production.
Chen et al. (2018) studied the role of estrogen on the
regulation of IOP and, consequently, on the status of retinal
ganglion cells, evaluating the effect of the lack of aromatase, an
enzyme necessary for the production of estrogens. To perform
this study both wild type and aromatase knockout mice were
compared (based on age and sex). The knockout females showed
significantly higher IOP levels compared to wild type females
of the same age and significantly lower RGC levels. The male
mice, on the other hand, did not show any significant difference
between the two groups as regards the IOP, although the 12
week knockouts showed a reduced RGC count compared to the
wildtype of the same age. These results further confirm the role
of estrogens in regulating IOP, reducing it and ensuring optimal
RGC status.
Vajaranant and Pasquae (2012) noted that estrogen may also
be involved in the aging process of the optic nerve, which appears
to be accelerated in the presence of an estrogenic deficiency. In
addition, studies aimed at assessing the possibility of estrogen
influencing the topography of the optic nerve head have shown
that the menstrual cycle-related fluctuations significantly modify
the central area and the edge of the optic nerve head, results
that should be taken into consideration in the follow-up of
young women with glaucoma (Akar et al., 2004). All these
elements would allow us to hypothesize that a reduction in
estrogen concentrations leads to a greater susceptibility to the
development of glaucoma.
Some studies have focused their attention on genetic analysis,
trying to assess the existence of a possible correlation between
single nucleotide polymorphisms (SNPs) of genes involved
in estrogen metabolism and the development of POAG. For
example, SNPs in the endothelial nitric oxide synthase (eNOS3), a
gene regulated by estrogens, seem to be effectively correlated with
the development of open- angle glaucoma (Ball and Knuppen,
1980; Furchgott and Zawaszki, 1980; Pasquale et al., 2013).
Pasquale et al. (2013) have shown that, among women, some
SNPs were related to global POAG and to high-pressure POAG,
but not to those with low intraocular pressure; in men, however,
no type of correlation was observed. Also within the female
sample it was observed that the gene most associated with both
forms of open angle glaucoma appeared to be that of catechol-O-
methyltransferase, an enzyme that is involved in the methylation
of two estradiol derivatives, a process that seems to reduce the
bioavailability of estrogens. In conclusion, links between the
SNPs of the estrogenic pathways and the onset of glaucoma were
observed, but only for some types and exclusively in women.
Leber’s Hereditary Optic Neuropathy
Leber’s hereditary optic neuropathy (LHON), the most common
mitochondrial disease, is due to punctiform mutations of
mitochondrial DNA, transmitted by maternal inheritance.
LHON is characterized by RGC degeneration, with optic nerve
atrophy and loss of central vision (Man et al., 2003; Carelli et al.,
Frontiers in Neuroscience | www.frontiersin.org 5 February 2019 | Volume 13 | Article 57
Nuzzi et al. Sex Hormones and Optic Nerve
2004). It affects males more often than females and has its onset
in young adulthood. Since it is a genetic disease with maternal
inheritance, its incidence should theoretically be equal between
the sexes. Its higher occurrence in males could be due to the
protective effect of estrogens in women who, though carrying the
genetic mutation, do not develop the disease.
To test this hypothesis, Giordano et al. (2011) used as a
model cybrids, i.e., cytoplasmic hybrids or eukaryotic cell lines
produced by the fusion of a whole cell (cytoplasm and nucleus)
within a cytoplast (an enucleated cell), which were treated with
ICI 182780, an estrogen receptor antagonist, during the first
stage of the study. The cybrids presenting the typical mutations
of LHON presented higher oxygen reactive species levels than
the control cybrids, with greater apoptosis and less cell viability.
In the second stage of the study, 17β-estradiol was administered
to both groups of cybrids, which led to an improvement in
the experimental group due to the activation of superoxide
dismutase by E2 and activation of mitochondrial biogenesis and
a slight, albeit significant, increase in energy production. These
results appear to corroborate the potential role of estrogens in
preventing the development of LHON in females. The findings
also provide an explanation for a hormone-correlated metabolic
basis for the prevalence of LHON in males, and open horizons
for designing treatments with estrogens or their analogs.
Building on these findings, the same research group
conducted a study (Pisano et al., 2015) again using cybrids and
observed that estrogen administration protected the mutated
cells via the activation of ERβ in the mitochondria of the
RGCs. The protective effect of estrogen was confirmed by
the fact that administration of receptor antagonist inhibited
the protective action of the estrogens. The aim of the study
was to determine whether use of ERβ as a target for potential
estrogen therapy could prevent or delay LHON in carriers
of the genetic mutations associated with its development:
findings provide evidence that phytoestrogen can correct in
vitro the cellular pathologic phenotype associated with LHON
mutations, in both cybrids and patient derived fibroblasts. If
further studies confirm these initial findings, estrogen therapy
may have significant implications for the course of the disease,
since no current therapy has a particularly positive effect in the
acute phase.
Nonarteritic Anterior Ischemic Optic
Neuropathy
NAION refers to optic nerve stroke caused by ischemia of the
axons of the RGCs (Hayreh, 1974). It is the most common cause
of sudden loss of vision associated with the optic nerve after age
50 years (Miller, 1980).
Studies using rodent models have evaluated whether estrogens
have a protective action (Bernstein et al., 2007). NAION was
induced in ovariectomized mice given either estradiol or placebo.
The results showed that although estrogen-correlated transcript
expression was augmented, it was not influenced by systemic
estrogen administration and there was no difference in the
number of surviving RGCs, indicating that probably estrogens
exert no protective action against NAION.
Optic Neuritis
Optic neuritis is an inflammation of the optic nerve often
associated with multiple sclerosis (MS): it manifests as the
first sign of disease in 20% of cases (Miller et al., 2005) and
affects 30–70% of persons with MS during their lifetime
(Frohman et al., 2008).
Studies investigating sex-related differences in RNFL thinning
measured using OCT at 6 months after the acute event (Costello
et al., 2012) showed that, on average, men were older than
women, were more likely to have relapsing or remitting MS, and
less thinning of the RNFL, with greater changes as compared to
basal values.
Taking as an example the demyelinating optical neuritis,
characteristic of MS, it is important to underline that, although
in some aspects the pathogenesis of optic nerve and retinal
pathologies present common elements, there is an important
difference due to the fact that retinal pathologies may be due
to the injury or malfunction of various cell types, including
photoreceptors, bipolar cells, ganglion cells and glia cells. Optic
nerve neuropathies depend almost exclusively on damage
to ganglion cells or nerve fibers; the latter include pathologies
affecting the vessels, responsible for vascularization and trophism
of the nerve, and those affecting myelin, which covers the axons
constituting the nerve.
Various studies analyzed the possible relationship between
sex hormones and myelin formation, especially in the
context of demyelinating diseases such as MS: Sicotte et al.
(2002), starting from the observation that women with MS
in pregnancy have a reduction of relapses, showed that
administration of estriol, a hormone typical of pregnancy,
showed a beneficial effect on the history of MS even in
non-pregnant women; Soldan et al. (2003), subsequently
identified as the likely cause of this phenomenon the
immunomodulatory effect of oral estriol therapy. More
recently, scientists tried to understand the effects of a
combination therapy of 17-β estradiol and intravenous adipose-
derived mesenchymal stem cell (ADSC) transplantation.
Results showed that 17-β estradiol increased the efficacy of
intravenous ADSCs in remyelination of corpus callosum axons
(Ragerdi Kashani et al., 2012).
Kim et al. (2018) tried to understand through which
mechanism estrogens favor the remyelination and they
have discovered that pathways involved are that of the ER
β. Further research has shown that the activation of this
receptor occurs both at the level of the brain immune cells
(CD11c+), and on the oligodendrocytes; the action on CD11c+
immunomodulatory cells would seem essential to favor the
correct maturation of oligodendrocytes, suggesting the need
for a synergistic action of estrogen on the two categories
of cells.
Progesterone and its derivatives have also been shown to have
beneficial activities in this field, being able not only to reduce
the extent of myelin sheath loss in MS, but also to promote the
formation of new myelin (El-Etr et al., 2015).
The possible role of androgens has also been examined
because, since these diseases affect males less frequently
than women. A protective effect of testosterone has been
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hypothesized; some studies have shown that testosterone, acting
on neural androgen receptors, stimulates myelin repair and has
an anti-inflammatory action (Hussain et al., 2013).
Therefore, sex hormones seem to play a role in myelin
regeneration during demyelinating pathologies, evidence that
could play an important role not only in the specific therapy
of these pathologies, but also in associated manifestations that
present the same pathogenesis, such as optic neuritis.
Another inflammatory disease of the optic nerve in which
a relationship between hormones and neuroretinal disease has
been suggested is neuromyelitis optica spectrum disorder with
aquaporin-4-immunoglobulin G (NMOSD-AQP4) (Wingerchuk
et al., 2015), a relapsing demyelinating inflammatory disease
characterized by uni- or bilateral optic neuritis, acute myelitis,
and higher prevalence among females (Wingerchuk, 2009).
In their study on the relationship between sex and clinical
manifestations of the disease, Kim et al. (2017) found that its
onset is later in men than in women (average 49 vs. 41 years of
age), neuritic attacks are less frequent at onset (17 vs. 44%), and
are less frequent during the course of the disease (0.08 vs. 0.27 per
year) in men than in women. Males more often tend to develop
an isolated form of myelitis (67 vs. 28%). Visual evoked potential
testing showed a shorter latency of P100 in men. Men were also
noted to have fewer acute optic neuritis attacks, independent of
age at onset of the disease. However, this type of optic neuritis is
less known and deserves further study.
Optic Nerve Tumors: Glioma and
Meningioma
Some researchers investigated the role of sex hormones in
the pathogenesis of various tumors, including the ones that
frequently affect the optic nerve, gliomas and meningiomas.
Different studies evaluated the existence of correlation
between reproductive factors and the risk of the onset of
glioma. Although most of the reproductive factors (eg., age
at menopause, number of pregnancies) were not related to
the development of this type of cancer (Felini et al., 2009), an
increased age at menarche was found to be a potential risk factor
for glioma development according to various studies (Felini
et al., 2009; Qi et al., 2013; Anic et al., 2014; Krishnamachari et al.,
2014). Specifically, Anic et al. (2014) found that this increased
susceptibility to the development of glioma in women with an
older age at menarche is present only in premenopausal women,
whereas this correlation is lacking after menopause. The analysis
by Felini et al. (2009) found that the correlation glioma- age at
menarche is strong only in cases of non-glioblastoma histologies.
These findings would agree with the hypothesis that prolonged
exposure to estrogen plays a protective role, reducing the risk
of developing this tumor, a hypothesis partly supported by data
from the analysis of the relationship between glioma and OC
and/or HRT, although in this case results are at times conflicting.
Some studies in literature agree in identifying a reduction of the
risk of glioma in subjects undergoing hormone therapy, be it OC
(Qi et al., 2013; Anic et al., 2014; Krishnamachari et al., 2014)
or HRT (Qi et al., 2013; Krishnamachari et al., 2014), others,
on the contrary, identified an increase in risk for HRT based
on estrogen only, but not for HRT based on estroprogestestinal
(Andersen et al., 2013a; Benson et al., 2015).
Other researchers focused attention on another frequent
tumor that affects the optic nerve, the meningioma. In this
case the risk of developing tumor is higher in women who
had undergone OC (Michaud et al., 2010; Claus et al., 2013)
or HRT (Michaud et al., 2010; Andersen et al., 2013b; Benson
et al., 2015); the type of HRT most likely associated with
meningioma is not yet clear, since according to some studies the
risk is higher with therapies based only on estrogens (Benson
et al., 2015), while according to others it is higher in therapies
with combination of estroprogestestinal (Andersen et al.,
2013b).
Although sex hormones would seem to be related to the onset
of these tumors, apparently in opposite way in the case of glioma
and meningioma, studies in this area are too few to be able to
define these results as definitive.
CONCLUSIONS
This review presents the current state of the art of the possible
relationship between sex hormones and optic nerve disorders
(Table 2). As noted in other ophthalmic disorders, as retinal
diseases (Nuzzi et al., 2018), sex hormones seem to be involved
in optic nerve disorders and may play an important role in
their prevention and in their therapeutic use. Although current
evidence is still insufficient for drawing conclusions, it does
provide starting points for experimental and clinical studies that
may ultimately inform clinical practice.
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